Pfizer is a global leader in developing medicines for patients suffering from chronic immune diseases. Pfizer's commitment to the discovery and development of novel therapeutics to help patients living with chronic autoimmune diseases is evidenced by products such as Xeljanz® (tofacitinib citrate), Celebrex® (celecoxib capsules), Rapamune® (sirolimus), and Enbrel® (etanercept) for patients suffering from conditions such as osteoarthritis, solid organ transplant rejection, rheumatoid arthritis, and psoriasis. Pfizer is interested in entering into strategic relationship with innovative collaborators to develop increasingly novel and differentiated therapies for autoimmune diseases.

WRD is interested in establishing alliances to develop therapeutics, expand disease biology understanding, and identify biomarkers that impact:

  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
  • Inflammatory GI disorders (i.e., Inflammatory Bowel Disease)
  • Psoriasis
  • Multiple Sclerosis
  • Type 1 Diabetes
  • Other indications with high unmet need that are mechanistically related to those above

Specific areas of interest include:

  • Cytokines and their signaling pathways
  • Adaptive Immunity, Lymphocyte biology including Th17 lymphocytes
  • Regulatory cells and Tolerance induction
  • Host-microbial interactions and microbiome
  • Technology platforms and products to help understand patient segmentation in the disease areas of interest and develop precision medicine strategies for innovative portfolio products
  • Technology platforms and prodcuts that allow for greater tissue and cell specific delivery

Not actively seeking partnering opportunities in:

  • Adequately controlled RA
  • TNFα, IL-1β targeting biologics
  • B cell depleting biologics
  • Corticosteroids


R & D Brochure


Understand what R&D is looking for in an early stage opportunity.


Connect With Us


Reach out. We want to hear from you.